Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1988 Jun;81(6):1653–1660. doi: 10.1172/JCI113501

Lowering cholesterol, 1988. Rationale, mechanisms, and means.

R J Havel 1
PMCID: PMC442606  PMID: 3290249

Full text

PDF
1653

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angelin B., Raviola C. A., Innerarity T. L., Mahley R. W. Regulation of hepatic lipoprotein receptors in the dog. Rapid regulation of apolipoprotein B,E receptors, but not of apolipoprotein E receptors, by intestinal lipoproteins and bile acids. J Clin Invest. 1983 Apr;71(4):816–831. doi: 10.1172/JCI110835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baker S. G., Joffe B. I., Mendelsohn D., Seftel H. C. Treatment of homozygous familial hypercholesterolaemia with probucol. S Afr Med J. 1982 Jul 3;62(1):7–11. [PubMed] [Google Scholar]
  3. Bilheimer D. W., Grundy S. M., Brown M. S., Goldstein J. L. Mevinolin stimulates receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Trans Assoc Am Physicians. 1983;96:1–9. [PubMed] [Google Scholar]
  4. Blankenhorn D. H., Nessim S. A., Johnson R. L., Sanmarco M. E., Azen S. P., Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987 Jun 19;257(23):3233–3240. [PubMed] [Google Scholar]
  5. Brown M. S., Goldstein J. L. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986 Apr 4;232(4746):34–47. doi: 10.1126/science.3513311. [DOI] [PubMed] [Google Scholar]
  6. Canner P. L., Berge K. G., Wenger N. K., Stamler J., Friedman L., Prineas R. J., Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986 Dec;8(6):1245–1255. doi: 10.1016/s0735-1097(86)80293-5. [DOI] [PubMed] [Google Scholar]
  7. Carew T. E., Schwenke D. C., Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7725–7729. doi: 10.1073/pnas.84.21.7725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chao Y. S., Windler E. E., Chen G. C., Havel R. J. Hepatic catabolism of rat and human lipoproteins in rats treated with 17 alpha-ethinyl estradiol. J Biol Chem. 1979 Nov 25;254(22):11360–11366. [PubMed] [Google Scholar]
  9. Davignon J., Gregg R. E., Sing C. F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988 Jan-Feb;8(1):1–21. doi: 10.1161/01.atv.8.1.1. [DOI] [PubMed] [Google Scholar]
  10. East C., Alivizatos P. A., Grundy S. M., Jones P. H., Farmer J. A. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med. 1988 Jan 7;318(1):47–48. doi: 10.1056/NEJM198801073180111. [DOI] [PubMed] [Google Scholar]
  11. Fielding C. J., Fielding P. E. Cholesterol transport between cells and body fluids. Role of plasma lipoproteins and the plasma cholesterol esterification system. Med Clin North Am. 1982 Mar;66(2):363–373. doi: 10.1016/s0025-7125(16)31425-0. [DOI] [PubMed] [Google Scholar]
  12. Freedman D. S., Cresanta J. L., Srinivasan S. R., Webber L. S., Berenson G. S. Longitudinal serum lipoprotein changes in white males during adolescence: the Bogalusa Heart Study. Metabolism. 1985 Apr;34(4):396–403. doi: 10.1016/0026-0495(85)90231-8. [DOI] [PubMed] [Google Scholar]
  13. Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237–1245. doi: 10.1056/NEJM198711123172001. [DOI] [PubMed] [Google Scholar]
  14. Goldbourt U. High risk versus public health strategies in primary prevention of coronary heart disease. Am J Clin Nutr. 1987 May;45(5 Suppl):1185–1192. doi: 10.1093/ajcn/45.5.1185. [DOI] [PubMed] [Google Scholar]
  15. Goldstein J. L., Brown M. S. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem. 1977;46:897–930. doi: 10.1146/annurev.bi.46.070177.004341. [DOI] [PubMed] [Google Scholar]
  16. Goldstein J. L., Ho Y. K., Basu S. K., Brown M. S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A. 1979 Jan;76(1):333–337. doi: 10.1073/pnas.76.1.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gotto A. M., Jr, Pownall H. J., Havel R. J. Introduction to the plasma lipoproteins. Methods Enzymol. 1986;128:3–41. doi: 10.1016/0076-6879(86)28061-1. [DOI] [PubMed] [Google Scholar]
  18. Grundy S. M., Vega G. L., Bilheimer D. W. Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia. Ann Intern Med. 1985 Sep;103(3):339–343. doi: 10.7326/0003-4819-103-3-339. [DOI] [PubMed] [Google Scholar]
  19. Grundy S. M., Vega G. L. Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J Lipid Res. 1985 Dec;26(12):1464–1475. [PubMed] [Google Scholar]
  20. Havel R. J. Dietary regulation of plasma lipoprotein metabolism in humans. Prog Biochem Pharmacol. 1983;19:110–122. [PubMed] [Google Scholar]
  21. Havel R. J. Functional activities of hepatic lipoprotein receptors. Annu Rev Physiol. 1986;48:119–134. doi: 10.1146/annurev.ph.48.030186.001003. [DOI] [PubMed] [Google Scholar]
  22. Havel R. J. George Lyman Duff memorial lecture. Role of the liver in atherosclerosis. Arteriosclerosis. 1985 Nov-Dec;5(6):569–580. doi: 10.1161/01.atv.5.6.569. [DOI] [PubMed] [Google Scholar]
  23. Havel R. J., Hunninghake D. B., Illingworth D. R., Lees R. S., Stein E. A., Tobert J. A., Bacon S. R., Bolognese J. A., Frost P. H., Lamkin G. E. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Ann Intern Med. 1987 Nov;107(5):609–615. doi: 10.7326/0003-4819-107-5-609. [DOI] [PubMed] [Google Scholar]
  24. Havel R. J., Kane J. P. Drugs and lipid metabolism. Annu Rev Pharmacol. 1973;13:287–308. doi: 10.1146/annurev.pa.13.040173.001443. [DOI] [PubMed] [Google Scholar]
  25. Havel R. J., Yamada N., Shames D. M. Role of apolipoprotein E in lipoprotein metabolism. Am Heart J. 1987 Feb;113(2 Pt 2):470–474. doi: 10.1016/0002-8703(87)90616-8. [DOI] [PubMed] [Google Scholar]
  26. Hofmann S. L., Russell D. W., Brown M. S., Goldstein J. L., Hammer R. E. Overexpression of low density lipoprotein (LDL) receptor eliminates LDL from plasma in transgenic mice. Science. 1988 Mar 11;239(4845):1277–1281. doi: 10.1126/science.3344433. [DOI] [PubMed] [Google Scholar]
  27. Hornick C. A., Kita T., Hamilton R. L., Kane J. P., Havel R. J. Secretion of lipoproteins from the liver of normal and Watanabe heritable hyperlipidemic rabbits. Proc Natl Acad Sci U S A. 1983 Oct;80(19):6096–6100. doi: 10.1073/pnas.80.19.6096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Illingworth D. R. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia. Ann Intern Med. 1984 Nov;101(5):598–604. doi: 10.7326/0003-4819-101-5-598. [DOI] [PubMed] [Google Scholar]
  29. Innerarity T. L., Weisgraber K. H., Arnold K. S., Mahley R. W., Krauss R. M., Vega G. L., Grundy S. M. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci U S A. 1987 Oct;84(19):6919–6923. doi: 10.1073/pnas.84.19.6919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Kane J. P., Havel R. J. Treatment of hypercholesterolemia. Annu Rev Med. 1986;37:427–435. doi: 10.1146/annurev.me.37.020186.002235. [DOI] [PubMed] [Google Scholar]
  31. Kane J. P., Malloy M. J. Treatment of hypercholesterolemia. Med Clin North Am. 1982 Mar;66(2):537–550. doi: 10.1016/s0025-7125(16)31434-1. [DOI] [PubMed] [Google Scholar]
  32. Kane J. P., Malloy M. J., Tun P., Phillips N. R., Freedman D. D., Williams M. L., Rowe J. S., Havel R. J. Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med. 1981 Jan 29;304(5):251–258. doi: 10.1056/NEJM198101293040502. [DOI] [PubMed] [Google Scholar]
  33. Kesaniemi Y. A., Beltz W. F., Grundy S. M. Comparison of clofibrate and caloric restriction on kinetics of very low density lipoprotein triglycerides. Arteriosclerosis. 1985 Mar-Apr;5(2):153–161. doi: 10.1161/01.atv.5.2.153. [DOI] [PubMed] [Google Scholar]
  34. Kita T., Nagano Y., Yokode M., Ishii K., Kume N., Ooshima A., Yoshida H., Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5928–5931. doi: 10.1073/pnas.84.16.5928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Knuiman J. T., West C. E., Katan M. B., Hautvast J. G. Total cholesterol and high density lipoprotein cholesterol levels in populations differing in fat and carbohydrate intake. Arteriosclerosis. 1987 Nov-Dec;7(6):612–619. doi: 10.1161/01.atv.7.6.612. [DOI] [PubMed] [Google Scholar]
  36. Koo C., Wernette-Hammond M. E., Innerarity T. L. Uptake of canine beta-very low density lipoproteins by mouse peritoneal macrophages is mediated by a low density lipoprotein receptor. J Biol Chem. 1986 Aug 25;261(24):11194–11201. [PubMed] [Google Scholar]
  37. Lin D. S., Connor W. E. The long term effects of dietary cholesterol upon the plasma lipids, lipoproteins, cholesterol absorption, and the sterol balance in man: the demonstration of feedback inhibition of cholesterol biosynthesis and increased bile acid excretion. J Lipid Res. 1980 Nov;21(8):1042–1052. [PubMed] [Google Scholar]
  38. Mabuchi H., Sakai T., Sakai Y., Yoshimura A., Watanabe A., Wakasugi T., Koizumi J., Takeda R. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. N Engl J Med. 1983 Mar 17;308(11):609–613. doi: 10.1056/NEJM198303173081101. [DOI] [PubMed] [Google Scholar]
  39. Malloy M. J., Kane J. P., Kunitake S. T., Tun P. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med. 1987 Nov;107(5):616–623. doi: 10.7326/0003-4819-107-5-616. [DOI] [PubMed] [Google Scholar]
  40. Moulin P., Bourdillon M. C., de Parscau L., Perrot L., Ponsin G., Berthezene F. High density lipoprotein alterations induced by bezafibrate in healthy male volunteers. Atherosclerosis. 1987 Sep;67(1):17–22. doi: 10.1016/0021-9150(87)90260-7. [DOI] [PubMed] [Google Scholar]
  41. Norman D. J., Illingworth D. R., Munson J., Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med. 1988 Jan 7;318(1):46–47. doi: 10.1056/NEJM198801073180110. [DOI] [PubMed] [Google Scholar]
  42. Oliver M. F. Prevention of coronary heart disease--propaganda, promises, problems, and prospects. Circulation. 1986 Jan;73(1):1–9. doi: 10.1161/01.cir.73.1.1. [DOI] [PubMed] [Google Scholar]
  43. Parthasarathy S., Young S. G., Witztum J. L., Pittman R. C., Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest. 1986 Feb;77(2):641–644. doi: 10.1172/JCI112349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Phillips N. R., Havel R. J., Kane J. P. Levels and interrelationships of serum and lipoprotein cholesterol and triglycerides. Association with adiposity and the consumption of ethanol, tobacco, and beverages containing caffeine. Arteriosclerosis. 1981 Jan-Feb;1(1):13–24. doi: 10.1161/01.atv.1.1.13. [DOI] [PubMed] [Google Scholar]
  45. Ross R. The pathogenesis of atherosclerosis--an update. N Engl J Med. 1986 Feb 20;314(8):488–500. doi: 10.1056/NEJM198602203140806. [DOI] [PubMed] [Google Scholar]
  46. Schrott H. G., Clarke W. R., Wiebe D. A., Connor W. E., Lauer R. M. Increased coronary mortality in relatives of hypercholesterolemic school children: the Muscatine study. Circulation. 1979 Feb;59(2):320–326. doi: 10.1161/01.cir.59.2.320. [DOI] [PubMed] [Google Scholar]
  47. Spady D. K., Dietschy J. M. Dietary saturated triacylglycerols suppress hepatic low density lipoprotein receptor activity in the hamster. Proc Natl Acad Sci U S A. 1985 Jul;82(13):4526–4530. doi: 10.1073/pnas.82.13.4526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Stamler J., Wentworth D., Neaton J. D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986 Nov 28;256(20):2823–2828. [PubMed] [Google Scholar]
  49. Steinberg D. Lipoproteins and atherosclerosis. A look back and a look ahead. Arteriosclerosis. 1983 Jul-Aug;3(4):283–301. doi: 10.1161/01.atv.3.4.283. [DOI] [PubMed] [Google Scholar]
  50. Talmud P. J., Barni N., Kessling A. M., Carlsson P., Darnfors C., Bjursell G., Galton D., Wynn V., Kirk H., Hayden M. R. Apolipoprotein B gene variants are involved in the determination of serum cholesterol levels: a study in normo- and hyperlipidaemic individuals. Atherosclerosis. 1987 Sep;67(1):81–89. doi: 10.1016/0021-9150(87)90267-x. [DOI] [PubMed] [Google Scholar]
  51. Tobert J. A. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation. 1987 Sep;76(3):534–538. doi: 10.1161/01.cir.76.3.534. [DOI] [PubMed] [Google Scholar]
  52. Tyroler H. A. Review of lipid-lowering clinical trials in relation to observational epidemiologic studies. Circulation. 1987 Sep;76(3):515–522. doi: 10.1161/01.cir.76.3.515. [DOI] [PubMed] [Google Scholar]
  53. Virmani R., Robinowitz M., Geer J. C., Breslin P. P., Beyer J. C., McAllister H. A. Coronary artery atherosclerosis revisited in Korean war combat casualties. Arch Pathol Lab Med. 1987 Oct;111(10):972–976. [PubMed] [Google Scholar]
  54. Witztum J. L., Young S. G., Elam R. L., Carew T. E., Fisher M. Cholestyramine-induced changes in low density lipoprotein composition and metabolism. I. Studies in the guinea pig. J Lipid Res. 1985 Jan;26(1):92–103. [PubMed] [Google Scholar]
  55. Yamada N., Shames D. M., Havel R. J. Effect of low density lipoprotein receptor deficiency on the metabolism of apolipoprotein B-100 in blood plasma. Kinetic studies in normal and Watanabe heritable hyperlipidemic rabbits. J Clin Invest. 1987 Aug;80(2):507–515. doi: 10.1172/JCI113099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Yamamoto A., Matsuzawa Y., Yokoyama S., Funahashi T., Yamamura T., Kishino B. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol. 1986 Jun 27;57(16):29H–35H. doi: 10.1016/0002-9149(86)90434-0. [DOI] [PubMed] [Google Scholar]
  57. Yamamoto T., Bishop R. W., Brown M. S., Goldstein J. L., Russell D. W. Deletion in cysteine-rich region of LDL receptor impedes transport to cell surface in WHHL rabbit. Science. 1986 Jun 6;232(4755):1230–1237. doi: 10.1126/science.3010466. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES